Related Experiment Videos

Phase variations of the Mycoplasma penetrans main surface lipoprotein increase antigenic diversity

O Neyrolles1, I Chambaud, S Ferris

  • 1Unité d'Oncologie Virale, Institut Pasteur, 75724 Paris Cedex 15, France.

Infection and Immunity
|March 20, 1999
PubMed

Insights

Mycoplasma penetrans, found in HIV-infected patients, exhibits P35 antigen phase variation. This immune evasion mechanism involves changes in surface lipoprotein expression, differing from other Mycoplasma species.

Area of Science:

  • Microbiology
  • Immunology
  • Virology

Background:

  • Mycoplasma penetrans is a recently identified bacterium associated with HIV infection.
  • A key antigen, P35 lipoprotein, is crucial for Mycoplasma penetrans serological assays.
  • This bacterium is isolated from urine samples of human immunodeficiency virus (HIV)-infected individuals.

Purpose of the Study:

  • To investigate the phenomenon of P35 antigen phase variation in Mycoplasma penetrans.
  • To elucidate the underlying mechanism of this variation and its implications for immune evasion.

Main Methods:

  • Analysis of P35 antigen expression and its correlation with colony immunoreactivity.
  • Investigation of gene transcription levels to understand variation at the molecular level.
  • Characterization of the P35 gene and its promoter for mutations or rearrangements.

Main Results:

  • Mycoplasma penetrans P35 antigen exhibits high-frequency spontaneous and reversible phase variation.
  • This variation is regulated at the transcriptional level and is not due to gene rearrangement or point mutations.
  • Phase variation is linked to altered expression of other lipoproteins, suggesting a coordinated gene family regulation.

Conclusions:

  • The P35 phase variation mechanism in Mycoplasma penetrans is distinct from other Mycoplasma species.
  • Altered surface antigen expression likely facilitates immune evasion in HIV-infected hosts.
  • Understanding this variation is critical for developing effective diagnostics and therapeutics for Mycoplasma penetrans infections.

Related Concept Videos